One of Australia's leading gastroenterologists says he believes that a clinically proven herbal product has its place among, and is probably at least as effective as, more expensive mainstream treatments for common gastrointestinal disorders that impact thousands of Australians.
Professor Gerald Holtmann, Director of the Department of Gastroenterology and Hepatology at Princess Alexandra Hospital, and Professor of Medicine at University of Queensland, said the Iberis amara (bitter candy tuft) combination herbal product is now a standard treatment for gastrointestinal disorders such as Irritable Bowel Syndrome and functional dyspepsia.
"These disorders are extremely common and impact quality of life in a number of ways. People cannot go out, they cannot enjoy a normal meal, and they have complaints like diarrhoea or constipation and often abdominal symptoms that mean they may be unable to work. "Moreover, due to the severity and the chronic nature of symptoms that cause frequent consultations with GPs and specialists, these disorders are a significant burden and challenge for the health care system."
Speaking at the Australian Gastroenterology Week Conference in Brisbane, Professor Holtmann said he was initially very sceptical that a complementary medicine could match other more established treatments. However, he says the accumulated scientific evidence, including his own trials, have demonstrated its efficacy.
"I was really stunned when I saw the results of the first placebo-controlled study. It was the most effective treatment I have ever seen in these patients. "And it is not just effective in regard to the symptoms. It is effective with regard to patients that were unable to work, which has huge economic implications. Based upon the millions of treatments and the thousands of patients who have been in clinical trials, this is an exceptionally well-tolerated medication."
Also at the conference, a leading medical researcher said a clinical trial currently underway involving the product had the potential to transform treatment procedures and significantly reduce costs associated with functional dyspepsia.
Professor Jane Andrews, Associate Professor of Gastroenterology at the Royal Adelaide Hospital and the University of Adelaide, is involved in conducting the trial that is comparing the effects of the Iberis amara combination herbal product, with the prescription drug, proton pump inhibitor (PPI), esomeprazole, as well as a placebo in patients with functional dyspepsia. Approximately $500 million is spent annually in Australia on PPIs.
She said prescription treatments for dyspepsia were "quite unsatisfactory", with only about a 10% improvement over a placebo. Yet up to 40% of the population suffers from unexplained indigestion at some point in time, which is almost certainly functional dyspepsia.
"This Iberis amara combination herbal product is a very interesting preparation because the manufacturer is willing to have it evaluated properly in clinical trials whereas a lot of other companies that produce complementary medicines make claims, yet are not prepared to put in any effort to evaluate those claims in a randomised, controlled trial environment.
"The other thing from the community perspective is that it's not a prescription product, so if it is equally effective or more effective than the PPI comparator, it would save a large amount on the Pharmaceutical Benefits Scheme. Also, it has got a very good safety profile," Professor Andrews said. The trial is funded by a grant from the National Health and Medical Research Council (NHMRC) and recruitment is due to be completed by the end of March next year.
In addition to bitter candy tuft, the product also contains angelica root, chamomile flowers, caraway fruit, St Mary's thistle fruit, balm leaves, peppermint leaves, greater celandine and liquorice root. It is manufactured in Germany and has been prescribed worldwide for 50 years to millions of people. Its efficacy has been examined in 14 clinical trials in more than 45,000 patients, with no serious side effects.
The product is available in Australia at selected pharmacies and health food stores, sold as a Practitioner Only product, dispensed by healthcare professionals. Always read the label. Use only as directed. If symptoms persist, consult your health care professional.
Craig Weller is the Managing Director of Flordis.
Question: Can you talk about Iberis amara combination herbal product and what disorders it is used to treat?
MORE